Vascular occlusion

Information

  • Patent Grant
  • 11832824
  • Patent Number
    11,832,824
  • Date Filed
    Thursday, July 18, 2019
    4 years ago
  • Date Issued
    Tuesday, December 5, 2023
    5 months ago
Abstract
An occlusive system for the vasculature and an embolic coil used in such an occlusive system is described. Also described is an occlusive plug which can be used for occlusive purposes within the vasculature.
Description
BACKGROUND OF THE INVENTION

Occlusion is often used as a treatment for various vascular disorders, such as aneurysm, atrial septal defect, left atrial appendage, patent foramen ovale, patent ductus arteriosis, and the like. The use of embolic coils is one method of occlusion. However, on occasion there are difficulties that can arise. For example, occlusion within the left atrial appendage can be particularly difficult because of the potential variance in the shape of the ostium of the left atrial appendage, and the potential variance in the shape and geometry of the left atrial appendage. Also, one possible complication with embolic coils is the risk of the coils falling out of the target treatment site within the vasculature. Accordingly, a system of occlusion utilizing embolic coils which mitigates the risk of the coils falling out of the target treatment site would be beneficial. Also beneficial would be devices and methods which improve the occluding process in general. Such a system would be widely useful for treating various disorders, including the occlusion of left atrial appendages, aneurysms, atrial septal defect, patent foramen ovale, patent ductus arteriosis, vessel shutdown and other similar vascular disorders.


SUMMARY OF THE INVENTION

In one embodiment an occlusive system comprises a containment bag and embolic coils.


In one embodiment an occlusive system comprises a containment bag, balloon, and embolic coils.


In another embodiment an embolic coil used in an occlusive system is described.


In another embodiment an occlusive system comprises a protective disk and embolic coils.


In another embodiment an occlusive system comprises a protective mesh, and embolic coils.


In another embodiment an occlusive system comprises a balloon and embolic coils.


In another embodiment an occlusive system includes an embolic coil having a sheet.


In another embodiment an embolic coil used in an occlusive system includes a sheet.


In another embodiment an occluder with an inner structure and outer structure is described.


In another embodiment an occluder with an inner structure and outer membrane layer is described.


In another embodiment an occluder with an inner and outer structure and intermediate membrane layer is described.


In another embodiment an occluder is collapsible.


In another embodiment an occluder is not collapsible.


These and other objects and features of the present invention will be appreciated upon consideration of the following drawings and detailed descriptions.





BRIEF DESCRIPTION OF THE DRAWINGS


FIGS. 1-5 are plan renderings of an occlusive system of one embodiment used to treat a vascular defect in accordance with the present invention.



FIGS. 6-12 are plan renderings of an occlusive system of another embodiment in accordance with the present invention.



FIG. 13 is a plan rendering of an occlusive system of another embodiment in accordance with the present invention.



FIG. 14 is a plan rendering an occlusive system of yet another embodiment in accordance with the present invention.



FIG. 15-16 are plan views of an embolic coil as used in an occlusive system in accordance with the present invention.



FIGS. 17-19 illustrate an occluder with an inner and outer structure in accordance with the present invention.



FIG. 20 illustrates the outer structure strut pattern of FIG. 17 in accordance with the present invention.



FIGS. 21-22 illustrate an occluder with an inner structure and outer membrane layer in accordance with the present invention.



FIG. 23 illustrates an occluder with an inner and outer structure and intermediate membrane layer in accordance with the present invention.



FIG. 24 illustrates a delivery system for an occluder in accordance with the present invention





DESCRIPTION OF EMBODIMENTS

I. Vascular Occlusion System


An occlusive system is used to occlude a vascular treatment site. In some of the examples specified, the occlusive system is used to treat the left atrial appendage, although the system could also be used for other purposes such as aneurysm occlusion or other occlusive purposes. The left atrial appendage is a pouch located in the left atrium. In some cases blood clots may form in the appendage. Over time thrombus from the clots may dislodge and lead to thrombus formation in other areas of the vasculature, leading to ischemic damage such as stroke. Thus occlusion of the left atrial appendage tends to limit and sometimes prevent this thrombus migration.


The embodiments described may be used to occlude left atrial appendages, atrial septal defects, patent foramen ovale, aneurysms, and other vascular disorders.



FIG. 1 shows an occlusive system. The system is deployed within the vasculature and placed in the vicinity of the left atrial appendage (LAA) 24. The system is deployed through a catheter 10 and includes a delivery tube 12. In one example the system is delivered through a guide catheter 10, in another example catheter 10 is a microcatheter which tube 12 is delivered through. A containment bag 20 sits near the distal end of the delivery tube. The containment bag includes a proximal stem section 22. In one example the containment bag 20 is a mesh comprising one or more metallic (i.e. nitinol, stainless steel, or cobalt-chromium) filaments. The mesh may also contain one or more radiopaque threads (i.e. platinum, palladium, or tantalum) woven through the mesh to increase radiopacity and visualization.


The delivery tube 12 has a stopper ring 18 near the distal end of the delivery tube 12; the stopper ring 18 is affixed to the inner surface of the delivery tube 12. A pusher 14 with a plunger 16 at the distal end of the pusher 14 is used to push the containment bag 20. The containment bag 20 is not constrained by the stopper ring 18. In one example the containment bag 20 is made of a highly conformable mesh to thus be able to adopt a flexible shape to navigate around the stopper ring 18. In another example the containment bag 20 has a tapered profile, or does not fill the delivery tube 12 and thus the stopper ring 18 does not limit the movement of the containment bag. The pusher 14 may be comprised of a metallic material (i.e. stainless steel, nitinol, cobalt-chromium or other materials) and has a larger diameter plunger 16 attached to the distal end of the pusher 14.


The delivery tube 12 is placed in the region of the ostium (neck or opening) 30 of the left atrial appendage 24. The delivery tube may be placed just proximal of the ostium, even with the ostium, or within the left atrial appendage. The user pushes pusher 14 in order to push the containment bag 20 into the LAA 24. The plunger 16 is prohibited from moving beyond a certain point by interacting with stopper ring 18. Once the pusher 14 is pushed to a certain point the plunger 16 hits the stopper ring 18 which limits any further movement. The plunger 16 pushes against the stem 22 of containment bag 20. Due to the force from the plunger 16, the containment bag 20 pushes into the LAA where the proximal part of the bag sits near the ostium while the distal portion sits within the LAA. Depending on the size of the cavity, the containment bag 20 may fill a substantial portion of the LAA, or sit mostly within the ostium. The intended function of containment bag 20 is to act as a filling receptacle for subsequently placed embolic coils, to prevent blood flow into and out of the target site.


In FIG. 2, pusher 14 is pushed to the point where plunger 16 hits stopper ring 18. Containment bag 20 is pushed into the LAA, and pusher 14 is withdrawn (FIG. 3). Referring to FIG. 4, another pusher 28 with distally attached embolic coil 26 is placed through tube 12. The embolic coil 26 is pushed into the containment bag 20. Thermal, electrolytic, or mechanical detachment means can be used to detach the coil 26 from the pusher 28. One such thermal detachment system that could be used is shown in U.S. Pat. No. 8,182,506, which is hereby incorporated by reference in its entirety. Another detachment system that could be used is shown in U.S. Pat. No. 6,620,152, which is hereby incorporated by reference in its entirety. With reference to FIG. 5, this procedure can be repeated to fill the bag with additional embolic coils 26. The coils 26 are retained within the containment bag 20 and the coils 26 form a solid embolic mass within the bag and fill the space at the neck of the malformation to prevent blood flow into the malformation.


Various types of embolic coils can be used to fill the containment bag. Examples include those described in U.S. Pat. Nos. 8,273,100, 8,066,036, 6,375,669, 6,015,424, 8,323,306, 8,377,091, and U.S. Pub. No. 2011/184455 all of which are hereby incorporated by reference in their entirety. The embolic coils can utilize polymers, hydrogels, and/or metals such as platinum, nitinol, stainless steel.


Another embodiment would incorporate a compliant balloon (not shown) with the containment bag occlusive system. In one example, the compliant balloon (not shown) would come pre-loaded in the distal portion of the containment bag 20 and thereby provide a buffer against which the coils would rest at the distal end of the containment bag 20. The balloon would be preloaded in the containment bag 20.


In another example, a balloon catheter would be situated so that the catheter balloon is placed at the neck of the malformation so that the coils do not fall out of the containment bag 20. Once the bag 20 is filed, the balloon would be detached from the catheter. In other words, the compliant balloon would be introduced after the embolic coiling procedure in order to seal the neck of the malformation and provide a proximal barrier for the embolic coils to prevent migration.


Although the embodiment as described above is shown for use for occluding a left atrial appendage, it could also be used for a variety of purposes including aneurysm, atrial septal defect, patent foramen ovale, or other occlusive purposes.


Another embodiment in accordance with the present invention is shown in FIGS. 6-12. An occlusive system comprises a tubular assembly 31 that has an inner tube 40 which is disposed within an outer tube 38. The outer tube 38 has a lumen to accommodate the inner tube 40, and the inner tube 40 also has a lumen.


A mesh structure 32 is disposed at the distal end of the tubular assembly 31 and is affixed to the distal end of the inner tube 40 at location 34 and to the distal end of the outer tube 38 at location 36. Such affixation can be made through various techniques known to those skilled in the art, including mechanical ties, chemical affixation, over-molding or various combinations thereof. The mesh structure 32 can be comprised of a mesh of nitinol, cobalt chromium, or other metallic wires. Radiopaque material (i.e. tantalum or platinum) may optionally be used in the mesh to enhance visualization.


The mesh structure 32 will generally have an elongated shape but will adopt a disk-like, bunched shape based on user manipulation of the tubular assembly 31, as will be explained in more detail below.


The inner tube 40 is movable relative to the outer tube 38. Since one end of the mesh structure 31 is attached to the outer tube 38 and its opposite end is attached to the inner tube 40, movement of inner tube 40 relative to the outer tube 38 will selectively cause the mesh structure 32 to adopt the shapes shown in FIGS. 7-10 as the inner tube is retracted.


For example, as the inner tube 40 is retracted relative to the outer tube 38, the mesh structure 32 will adopt a more bulged, disk-like shape. Such a shape can be useful for sealing the neck of the ostium of a treatment site (e.g., the ostium of a left atrial appendage). Once the mesh structure 32 is configured to a desired shape, e.g., a sealing shape, the inner tube 40 can be used to deliver embolic agents such as embolic coils to fill the treatment site, e.g., to fill a malformation.


Referring now to FIGS. 11-12, the proximal portion of the tubular assembly 31 is shown. The proximal portion includes a hemostatic valve 42 which is connected to a first fitting 46, which, in turn, is connected to outer tube 38. The first fitting 46 threadably engages a second fitting 48 of the hemostatic valve 42 in a male-female relationship. Hemostatic valve 42 includes a port 44. The hemostaticvalve 42 threadably engages with third fitting 50 in a male-female relationship. Through the channel of the hemostatic valve 42 and the third fitting 50, the inner tube 40 of the tubular assembly 31 extends.


When third fitting 50 is completely threaded over the hemostatic valve 42, the third I fitting 50 clamps down on the inner tube 40 and fixes it in place relative to the outer tube 38. In other words, the third fitting 50 can be used to lock the inner tube 40 in a position relative to the outer tube 38 and thereby fix the shape of mesh structure 32.


In one example, the inner tube 40 is retracted relative to the outer tube 38 to create an optimal ostium sealing shape for mesh structure 32. The third fitting 50 is then locked to maintain the sealing shape of the mesh structure 32 while embolic agents such as coils are delivered through the inner tube 40 to the vascular treatment site.


The proximal end of the inner tube 40 has an introducer section 52. Coils can be introduced through this section, or section 52 can be connected to a syringe or other device to introduce other embolic agents (i.e. liquid embolic) into the treatment site through the inner tube 40.


In this embodiment, inner tube 40 acts like a microcatheter since it can be used to introduce embolic material and outer tube 38 acts like a sheath for the inner tube 40.


A device in accordance with the present invention may be delivered through a guide catheter to a target treatment site. The guide catheter can be retracted or the mesh structure 32 can be pushed out from the guide catheter to expose the mesh structure 32. Once the device reaches the treatment site the user can manipulate the shape of the mesh structure 32 to seal the ostium or neck of the treatment site. Once the ostium is sealed the user can implant embolic agents via the inner tube 40 to fill the vasculature, while the mesh structure 32 will prevent the embolic agent from migrating. The embolic agents, in one example coils, will form an embolic mass to seal the interior of the malformation and thus prevent blood flow into the malformation/treatment site. The mesh structure 32 can then be retracted (via relative movement of inner tube 40 and outer tube 38) to its elongated shape and withdrawn.


In one example, the system of FIGS. 6-12 has a working length of 117 cm and an overall length of 135 cm and is compatible with a 0.018″ or 0.035″ embolic coil. The mesh structure 32 may have a compressed length of 0.7 cm and stretched length of 2.5 cm. Outer tube 38 can have an inner diameter of 0.079″ and outer diameter of 0.092″ while inner tube 40 can have an inner diameter of 0.053″ and outer diameter of 0.066″. In one example the mesh structure 32 has a fully stretched radius of 10 mm and a fully compressed radius of 35 mm, and thus could seal an ostium having a width of 10-35 mm. In one example, the system is delivered through an 8 or 8.5 F guide catheter.


Although the embodiment as just described is shown for occluding a left atrial appendage, it could also be used for a variety of purposes including aneurysm, atrial septal defect, patent foramen ovale, or other occlusive purposes.



FIG. 13 shows another embodiment of an occlusive system. In this embodiment a mesh 54 is placed at the distal end of tube 58. The mesh 54 can be comprised of a mesh of nitinol, cobalt chromium, or other metallic wires. Radiopaque material (i.e. tantalum or platinum) may optionally be used in the mesh 54 to enhance visualization.


Tube 58 is analogous to outer tube 38 of the previous embodiment; however, no inner tube is used in this embodiment. The proximal end of mesh 54 is affixed to the distal end of tube 58, and the distal end of mesh 54 is open. Mechanical ties, chemical affixation, over molding, or various combinations thereof may be used to affix the mesh to the distal part of tube 58. The mesh naturally has a flared shape useful for sealing the neck of the ostium or neck of the treatment site. An introducer, such as a hemostatic valve or other introducer system, is disposed at the proximal end of tube 58 and is used to introduce embolic coils or other embolic agents through tube 58.


In this embodiment, tube 58 acts like a microcatheter since it can be used to introduce embolic material.


The device may be delivered through a guide catheter to a target treatment site 24. Once at the treatment site the guide catheter is retracted or the mesh 54 is pushed out from the guide catheter. The open face of the mesh is placed just distal of the neck to seal the neck for the embolic agents that are subsequently introduced. Embolic agents, such as coils, are introduced through tube 58 and the mesh seals the neck of the treatment site in order to prevent the coils from falling out. The embolic agents will form an embolic mass within the treatment site and thereby cut off blood flow to said aneurysm, left atrial appendage, or vascular malformation. The mesh 54 can then be withdrawn.


In one example, the system of FIG. 13 has an overall length of 120 cm, a working length of 50 cm and the mesh 54 has a diameter of 10 millimeters and a stretched (i.e. when compressed in a delivery catheter) length of 3 cm and an unstretched (i.e. when in an unfurled deployed state) length of 1.5 cm. In one example, the system is delivered through an 8 or 8.5 F guide catheter.


Although the embodiment as just described is shown for occluding a left atrial appendage, it could also be used for a variety of purposes including aneurysm, atrial septal defect, patent foramen ovale, or other occlusive purposes.


In another embodiment shown in FIG. 14, the occlusive system utilizes an inflatable balloon 60 to seal the ostium. The occlusive system also utilizes a tube (e.g. microcatheter) 62 which sits proximal of the balloon and runs through the balloon. The tube 62 may incorporate an inflation lumen, or a separate inflation lumen can be used to inflate and deflate the balloon 60. The tube is used to introduce embolic agents (i.e. embolic coils).


The system is placed just distal of the treatment site and the balloon 60 is expanded at the neck or ostium 24. Embolic agents (i.e. coils) are then introduced through the tube into the malformation and the inflated balloon ensures the coils will not fall out. The embolic coils, if used, will be formed into an embolic mass, the balloon 60 can then be deflated and removed and the embolic mass will stay within the ostium to prevent blood flow into the malformation. Any polymer can be used on the balloon, such as PTFE.


In one example, tube 62 has an inner diameter of 0.072″ and an outer diameter of 0.092″ and the system has a working length of 101 cm and an overall length of 114 cm.


Though the embodiment as just described is shown for use for occluding a left atrial appendage, it could also be used for a variety of purposes including aneurysm, atrial septal defect, patent foramen ovale, or other occlusive purposes.


Various types of embolic coils can be used to fill the malformation, utilizing the occlusive systems described. Examples include those described in U.S. Pat. Nos. 8,273,100, 8,066,036, 6,375,669, 6,015,424, 8,323,306, 8,377,091 and U.S. Publication No. 2011/184455, all of which are hereby incorporated by reference in their entirety. The embolic coils can utilize polymers, hydrogels, and/or metals such as platinum, nitinol, stainless steel.


The coils will typically be delivered via a pusher, and a severing or degrading system is typically used to sever the coil from the pusher. Thermal, electrolytic, or mechanical detachment means can be used to detach the coil from the pusher. One such thermal detachment system that could be used is shown in U.S. Pat. No. 8,182,506, which is hereby incorporated by reference in their entirety. Another detachment system that could be used is shown in U.S. Pat. No. 6,620,152, which is hereby incorporated by reference in its entirety.


II. Embolic Coil



FIGS. 15-16 show an embolic coil that can be used with the occlusive system embodiments shown in FIGS. 1-14. Due to the potential size of the treatment site (e.g., left atrial appendage), as well as the potential for complex geometry, occlusion may be difficult.



FIGS. 15-16 illustrate an embolic coil 64 with a coupler or junction 68 which is connected to the pusher, this junction 68 can be degraded to release the embolic coil 64 at the treatment site. The coil 64 also includes a sheet 66 which is affixed to the coil 64. In one example the sheet 66 is glued or tied on one end to the coil 64 while the other end is free, the sheet 66 can be made of a polymer or can be a metallic mesh. In one example the sheet 66 is a rectangular or round/ovular/elliptical shape with a hole in it and which is placed over the coil 64 and tied, glued, or affixed via other means to the coil.



FIG. 15 shows the coil 64 with the sheet 66 in an expanded position. Multiple sheets 66 can be placed along the length of the embolic coil 64 and the addition of the sheets 66 increases the space filling potential of the coil 64 since one end of the sheet is open and thus free to fill open space within the treatment region. The sheet(s) 66 will also provide a fixation point for the coils 64 where the sheets 66 may contact the vessel wall thus promoting coil stability within the target region.



FIG. 16 shows the embolic coil 64 with the attached sheet 66 in a delivery configuration within a catheter 70. The embolic coil 64 described may also be used to occlude an aneurysm, atrial septal defect, patent foramen ovale, etc.


In one embodiment sheet 66 is a polymer, in another embodiment it is a braided metallic mesh, in another embodiment the sheet is a combination of a polymer and metallic mesh. In another embodiment the sheet(s) 66 are not affixed to the coil and are mobile along the length of the coil. In another embodiment the sheet(s) are not affixed to the coil at all and can be used independently (i.e. loading the sheets in lieu of using embolic coils, using the sheets first then following with coil occlusion).


It will be appreciated by one of ordinary skill in the art that the embodiments of FIGS. 1-16 can be used interchangeably. For example, the embodiments of FIGS. 1-5 could be used with the embodiments of FIGS. 6-12 by integrating the plunger/bag near the distal end of the inner catheter which runs through the mesh. Similarly, this concept could be incorporated on the embodiments of FIGS. 13-14.


III. Vascular Plug


One embodiment of a vascular plug in accordance with the present invention is shown in FIG. 17. The plug comprises an inner layer 100 and outer layer 120. The outer layer 120, which may be fabricated from a hypotube, acts as a frame or scaffold, and contacts the vessel wall in one or more locations to prevent the plug from migrating. The outer layer 120 may be metallic and comprised of nitinol, stainless steel, cobalt-chromium, various combinations thereof, or other materials. In one example, outer layer 120 is a laser cut nitinol hypotube.


The inner layer 100 comprises a mesh which can be heat set into particular shape (e.g., spherical). The inner layer 100 may be metallic and comprised of nitinol, stainless steel, cobalt-chromium, various combinations thereof, or other materials. The wires comprising inner layer 100 preferably have minimal gap to limit the amount of blood flow through the plug so as to promote occlusion of the treatment site. In one example inner layer 100 is a 144 wire braid with about a 96 micron pore size and 0.001″ OD wire.


In one example, outer layer 120 is comprised of 5-10 struts 130. In another example outer layer 120 is comprised of 6 struts 130 and has an elongated spherical shape. When viewed along an axis of the plug (i.e., when viewing either end of the plug along the plug axis), the proximal and distal ends of the outer layer 120 take on a star-like shape comprised of one or more cells 140 as shown in FIG. 20. The star shaped pattern shown in FIG. 20 is based on a 6 strut pattern in which each cell 140 considered to constitute one strut 130. The struts 130 then merge out into a more expanded, elongated spherical frame shape as shown in FIG. 17.



FIGS. 18-19 illustrate a vascular plug with an inner layer 100 and outer layer 120 where the outer layer 120 has a more spherical shape and which conforms more closely to the shape of the inner layer 100 as compared to the shape of outer layer 120 of FIG. 17. In one example of FIG. 18, this more spherically shaped outer layer would not have a star like strut at each end (as in FIG. 20) when viewed along the plug's axis.


Inner layer 100 may utilize radiopaque (i.e. tantalum, platinum, or gold) wires as part of the mesh to promote visualization within the vasculature. In another example shown in FIG. 19, radiopaque markers 150 may be used in select locations along outer layer 120 to enhance visualization. Markers 150 may also be used on the device of FIG. 17.



FIGS. 21-22 show another embodiment of a vascular plug in accordance with the present invention. This embodiment contains an inner structure which can be considered analogous to the outer layer 120 of the embodiment of FIG. 17. Instead of an inner layer 100, this embodiment utilizes a membrane 160 over a support structure 120. In one example the membrane 160 may be fixed to support structure 120. In another example, the membrane 16 may be heat set over support structure 120. In another example, adhesive may be used to bond membrane 160 to support structure 120. In one example, the membrane 160 is comprised of a polymer. In one example, that polymer may be ePTFE. In another example, polyester, polyurethane, or PLGA may be used. Radiopaque markers 150 similar to the ones shown in FIG. 19 may be mounted on support structure 120 to promote visualization. Similar to the inner layer 100 of the embodiment of FIG. 17, the membrane 160 substantially prevents blood flow in the vessel and promotes occlusion.



FIG. 23 shows another embodiment of a vascular plug in accordance with the present invention. This embodiment utilizes an outer structure 300, inner structure 310 (not visible in FIG. 23) and a membrane 320 sandwiched between the two structures. In one example, the inner and outer structures 300, 310 are spherical in shape and comprised of a mesh or braid. The proximal and distal ends of the braid layers may be crimped together with radiopaque markers 340. In one example, the markers 340 are stainless steel coated with tantalum. The markers 340 both tie the ends of the braid and allow the device to be visualized within the vasculature during deployment.


In one example, the distal marker crimp utilizes one marker for the inner structure 310 and a separate marker for the outer structure 300 and thus enables the two structures to expand independently from each other. In other words, such a configuration would allow the outer structure 300 to open before the inner structure 310 opens. The extent that each structure opens would depend on the heat set memory of each structure.


The plug is delivered in a collapsed state and expands upon deployment once deployed from the catheter and allows for a variable diffusive blood flow profile depending on the extent that the inner braid is opened. In other words, if the inner structure 310 is not fully opened, the pore size is smaller than if the inner structure 310 is in a fully opened state thus the plug would be more occlusive in nature in such a configuration. As such, in certain embodiments, the inner and outer structures 310, 300 are independently and controllably expandable relative to one another.


The membrane 320 may be comprised of a polymer. In one example, that polymer is ePTFE. In another example, polyester, polyurethane, or PLGA may be used. The inner structure 310 provides a foundation layer for the membrane 320, while the outer structure 300 provides increased restraining force to the membrane 320 while also providing another barrier for blood flow. In one example, the membrane 320 may be adhesively bonded, heat set, or tied to either the inner or outer structure, 310, 300 or both structures. In one example the inner and outer structures, 310, 300 are made with 48 wires, 0.0019″ diameter wire. In one example radiopaque wires (i.e. tantalum) are weaved into the braid to provide radiopacity. The structures 310, 300 may be heat set into the desired shape (e.g., spherical).


In another embodiment similar to the embodiment of FIG. 23, no inner structure is used and the membrane 320 is affixed only to the outer structure 300. Such fixation can be achieved through an adhesive, mechanically or by a heat set operation, etc.



FIG. 24 illustrates a delivery system used to deliver an occlusive plug in accordance with the present invention. The delivery system comprises a pusher 200 and a linkage 180. The linkage 180 is degradable to sever the plug from the pusher 200. In one example, pusher 200 is a push wire. In another example pusher 200 is a hypotube. Mechanical (e.g., screw threads), hydraulic, thermolytic, or electrolytic systems may be used to degrade linkage 180. One such detachment system that could be used is shown in U.S. Pat. No. 8,182,506, which is hereby incorporated by reference in its entirety. Another detachment system that could be used is shown in U.S. Pat. No. 6,620,152, which is also hereby incorporated by reference in its entirety. The device could be delivered through a catheter and is detached at the target site.


In one embodiment, the plug is collapsible and is delivered in a contracted shape in the catheter and adopts its enlarged deployed shape once deployed from the catheter. In another embodiment the plug is delivered through a catheter which is large enough to accommodate the plug in its deployed shape. As such, the plug is delivered and deployed in its final shape.


For any embodiment utilizing a membrane, the pore size of the membrane may be customized depending on the desired occlusion rate. A smaller pore size will generally occlude blood flow quicker than a larger pore size membrane. Thus if rapid occlusion is desired, a smaller pore size membrane is used and if slower occlusion is desired a larger pore size membrane is used. Alternatively, only a portion of the structure is covered with the membrane, e.g., a third or a half of the support structure is covered with the membrane, which will cause occlusion to take longer than if the complete structure is covered with the membrane.


Similarly, for any embodiments utilizing inner layer 100, the pore size of the inner layer 100 may be customized depending on the desired occlusion rate. A smaller pore size for the inner layer 100 is used when rapid occlusion is desirable, and a larger pore size for the inner layer 100 is used when slower occlusion is desirable.


For any of the above-described embodiments employing an inner layer or structure 100 and an outer layer or structure 120, the proximal and distal ends of the layers may be crimped together with radiopaque or non-radiopaque markers. In one example, the radiopaque markers are stainless steel coated with tantalum. Such markers serve to tie or bind the ends of the layers and, if radiopaque, allow the device to be visualized within the vasculature during deployment. The proximal ends of the inner layer or structure 100 and proximal ends of the outer layer or structure 120 may be crimped together or independently of one another. Likewise, the distal ends of the inner layer or structure 100 and proximal ends of the outer layer or structure 120 may be crimped together or independently of one another. Embodiments in which the ends of the inner layer or structure 100 and the outer layer or structure 120 are independently crimped allow for the inner layer or structure 10 and the outer layer or structure 120 to expand independent of one another. Accordingly, a variable diffusive blood flow profile is achieved depending upon the extent that the layers or structures are opened. For example, if the inner layer is not fully opened, the pore size would be smaller than the pore size when inner layer is in the fully opened state and thus more occlusive in nature). In other words, in certain embodiments, the inner and outer structures are independently and controllably expandable relative to one another.


Although the invention has been described in terms of particular embodiments and applications, one of ordinary skill in the art, in light of this teaching, can generate additional embodiments and modifications without departing from the spirit of or exceeding the scope of the claimed invention. Accordingly, it is to be understood that the drawings and descriptions herein are proffered by way of example to facilitate comprehension of the invention and should not be construed to limit the scope thereof.

Claims
  • 1. A vascular occlusion device to occlude a treatment site comprising: an outer tube;an inner tube positioned within and extending beyond the outer tube;a vascular plug attached distally to the inner tube and proximally to the outer tube, the vascular plug comprising an inner layer and an outer layer, wherein the inner layer comprises a mesh, and wherein the outer layer comprises a plurality of struts;a hemostatic valve connected to the outer tube; anda fitting connected adjacent to the hemostatic valve, the fitting being adjustable between a first configuration in which the fitting locks the inner tube relative to the outer tube to thereby fix a radial shape of the vascular plug and a second configuration in which the fitting does not lock the inner tube relative to the outer tube; an introducer located at and in fluid communication with a proximal end of the inner tube; and,where the inner tube can be pushed or pulled independently of the outer tube to control a radial shape of the vascular plug.
  • 2. The vascular occlusion device of claim 1, further comprising a first fitting connecting the outer tube to the hemostatic valve.
  • 3. The vascular occlusion device of claim 2, wherein the hemostatic valve includes a second fitting threadably connected to the first fitting.
  • 4. The vascular occlusion device of claim 1, where the inner tube contains a lumen used to convey embolic material.
  • 5. The vascular occlusion device of claim 4, wherein the introducer is attached to the proximal end of the inner tube, wherein the introducer is used to place an embolic material through the inner tube.
  • 6. The vascular occlusion device of claim 1, wherein the treatment site is a left atrial appendage.
  • 7. The vascular occlusion device of claim 1, wherein the fitting and the hemostatic valve are each independently operable.
  • 8. The vascular occlusion device of claim 7, wherein the fitting is axially offset with respect to the hemostatic valve.
  • 9. The vascular occlusion device of claim 1, wherein the fitting is threadably engaged with the hemostatic valve.
  • 10. The vascular occlusion device of claim 1, wherein the fitting is rotatable between the first configuration and the second configuration.
  • 11. A vascular occlusion system to occlude a treatment site comprising: an outer tube;an inner tube positioned within and extending beyond the outer tube, the inner tube having a lumen allowing passage of material through the inner tube and into the treatment site;a vascular plug attached distally to the inner tube and proximally to the outer tube, the vascular plug comprising an inner layer and an outer layer, wherein the inner layer comprises a mesh, wherein the outer layer comprises a plurality of struts, and wherein the vascular plug comprises a star-like shape comprising one or more cells when viewed from a proximal end or a distal end of the vascular plug;a hemostatic valve connected to the outer tube;where the inner tube can be pushed or pulled independently of the outer tube to radially expand the vascular plug;a locking mechanism connected adjacent to the hemostatic valve, the locking mechanism being adjustable between a first configuration in which the locking mechanism locks the inner tube relative to the outer tube to thereby fix a radial shape of the vascular plug and a second configuration in which the locking mechanism does not lock the inner tube relative to the outer tube; and, an introducer located at and in fluid communication with a proximal end of the inner tube.
  • 12. The vascular occlusion system of claim 11, wherein the hemostatic valve is attached to a proximal end of the outer tube.
  • 13. The vascular occlusion system of claim 12, further comprising a first fitting connecting the outer tube to the hemostatic valve.
  • 14. The vascular occlusion system of claim 13, wherein the hemostatic valve includes a second fitting threadably connected to the first fitting.
  • 15. The vascular occlusion system of claim 14, wherein the locking mechanism comprises a third fitting connected to a proximal end of the hemostatic valve.
  • 16. The vascular occlusion system of claim 11, further comprising an introducer attached to a proximal end of the inner tube, wherein the introducer is used to place an embolic substance through the inner tube to thereby occlude the treatment site.
  • 17. The vascular occlusion system of claim 11, wherein the treatment site is a left atrial appendage.
  • 18. The vascular occlusion system of claim 11, wherein the locking mechanism and the hemostatic valve are independently operable.
  • 19. The vascular occlusion system of claim 18, wherein the locking mechanism is axially offset with respect to the hemostatic valve.
  • 20. The vascular occlusion system of claim 11, wherein the locking mechanism is threadably engaged with the hemostatic valve.
RELATED APPLICATIONS

This application is a continuation of U.S. patent application Ser. No. 14/575,308 filed Dec. 18, 2014 entitled Vascular Occlusion, now issued as U.S. Pat. No. 10,398,441, which claims benefit of and priority to U.S. Provisional Application Ser. No. 61/919,667 filed Dec. 20, 2013 entitled Vascular Occlusion, and U.S. Provisional Application Ser. No. 61/924,662 filed Jan. 7, 2014 entitled Vascular Plug, all of which are hereby incorporated herein by reference in their entireties.

US Referenced Citations (271)
Number Name Date Kind
4364392 Strother et al. Dec 1982 A
4364492 Kong Dec 1982 A
5067489 Lind Nov 1991 A
5122136 Guglielmi et al. Jun 1992 A
5330483 Heaven et al. Jul 1994 A
5334210 Gianturco Aug 1994 A
5354309 Schnepp-Pesch et al. Oct 1994 A
5397331 Himpens et al. Mar 1995 A
5466242 Mori Nov 1995 A
5478331 Heflin Dec 1995 A
5496277 Termin et al. Mar 1996 A
5499995 Teirstein May 1996 A
5514093 Ellis et al. May 1996 A
5662711 Douglas Sep 1997 A
5713848 Dubrul Feb 1998 A
5718159 Thompson Feb 1998 A
5725552 Kotula et al. Mar 1998 A
5741333 Frid Apr 1998 A
5769816 Barbut Jun 1998 A
5814062 Sepetka et al. Sep 1998 A
5814064 Daniel et al. Sep 1998 A
5846261 Kotula et al. Dec 1998 A
5853422 Huebsch et al. Dec 1998 A
5861003 Latson et al. Jan 1999 A
5868778 Gershony Feb 1999 A
5919224 Thompson et al. Jul 1999 A
5925060 Forber Jul 1999 A
5941896 Kerr Aug 1999 A
5944738 Amplatz et al. Aug 1999 A
5947997 Pavenik et al. Sep 1999 A
5954745 Gertler et al. Sep 1999 A
6010498 Guglielmi Jan 2000 A
6019786 Thompson Feb 2000 A
6022336 Zadno-Azizi et al. Feb 2000 A
6024754 Engelson Feb 2000 A
6027520 Tsugita et al. Feb 2000 A
6059814 Ladd May 2000 A
6066149 Samson et al. May 2000 A
6113641 Leroy et al. Sep 2000 A
6142987 Tsugita Nov 2000 A
6152144 Lesh et al. Nov 2000 A
6176873 Ouchi Jan 2001 B1
6346117 Greenhalgh Feb 2002 B1
6355051 Sisskind Mar 2002 B1
6375668 Gifford et al. Apr 2002 B1
6379329 Nagireiter et al. Apr 2002 B1
6428557 Hilaire Aug 2002 B1
6428558 Jones et al. Aug 2002 B1
6451048 Berg et al. Sep 2002 B1
6468303 Amplatz et al. Oct 2002 B1
6550177 Epple, Jr. Apr 2003 B1
6585748 Jeffree Jul 2003 B1
6589265 Palmer et al. Jul 2003 B1
6652555 VanTassel et al. Nov 2003 B1
6685748 Day et al. Feb 2004 B1
6802851 Jones et al. Oct 2004 B2
6811560 Jones et al. Nov 2004 B2
6953472 Palmer et al. Oct 2005 B2
6994717 Kónya et al. Feb 2006 B2
7083632 Avellanet et al. Aug 2006 B2
7122058 Levine et al. Oct 2006 B2
7195636 Avellanet et al. Mar 2007 B2
7229461 Chin et al. Jun 2007 B2
7267694 Levine et al. Sep 2007 B2
7294146 Chew et al. Nov 2007 B2
7306624 Yodfat et al. Dec 2007 B2
7320065 Gosior et al. Jan 2008 B2
7326224 Houde Feb 2008 B2
7329285 Levine et al. Feb 2008 B2
7569066 Gerberding et al. Aug 2009 B2
7632291 Stephens et al. Dec 2009 B2
7632391 Cochran Dec 2009 B2
7645259 Goldman Jan 2010 B2
7665466 Figulla et al. Feb 2010 B2
7678129 Gesswein et al. Mar 2010 B1
7691124 Balgobin Apr 2010 B2
7695488 Berenstein et al. Apr 2010 B2
7713282 Frazier et al. May 2010 B2
7749238 Corcoran et al. Jul 2010 B2
7762943 Khairkhahan Jul 2010 B2
7981151 Rowe Jul 2011 B2
8034061 Amplatz et al. Oct 2011 B2
8043326 Hancock et al. Oct 2011 B2
8060183 Leopold et al. Nov 2011 B2
8062251 Goldman Nov 2011 B2
8066732 Paul et al. Nov 2011 B2
8083792 Boucher et al. Dec 2011 B2
8142456 Rosqueta et al. Mar 2012 B2
8152833 Zaver et al. Apr 2012 B2
8251948 Goldman Aug 2012 B2
8262719 Erickson et al. Sep 2012 B2
8280486 Miller et al. Oct 2012 B2
8308752 Tekulve Nov 2012 B2
8313505 Amplatz et al. Nov 2012 B2
8352014 Leipold et al. Jan 2013 B2
8357180 Feller, III et al. Jan 2013 B2
8361111 Widomski et al. Jan 2013 B2
8361138 Adams Jan 2013 B2
8398670 Amplatz et al. Mar 2013 B2
8408212 O'Brien et al. Apr 2013 B2
8425548 Connor Apr 2013 B2
8433391 Mark Apr 2013 B2
8442623 Nicoson et al. May 2013 B2
8454633 Amplatz et al. Jun 2013 B2
8460366 Rowe Jun 2013 B2
8480702 Kusleika et al. Jul 2013 B2
8491612 Stopek et al. Jul 2013 B2
8523940 Richardson et al. Sep 2013 B2
8636760 Garcia et al. Jan 2014 B2
8663301 Riina et al. Mar 2014 B2
8671815 Hancock et al. Mar 2014 B2
8679150 Janardhan et al. Mar 2014 B1
8685055 VanTassel et al. Apr 2014 B2
8690907 Janardhan et al. Apr 2014 B1
8696701 Becking et al. Apr 2014 B2
8715314 Janardhan et al. May 2014 B1
8715315 Janardhan et al. May 2014 B1
8715316 Janardhan et al. May 2014 B1
8715317 Janardhan et al. May 2014 B1
8715338 Frid May 2014 B2
8721676 Janardhan et al. May 2014 B1
8721677 Janardhan et al. May 2014 B1
8721707 Boucher et al. May 2014 B2
8728112 Evert et al. May 2014 B2
8728116 Janardhan et al. May 2014 B1
8728117 Janardhan et al. May 2014 B1
8728141 Riina et al. May 2014 B2
8733618 Janardhan et al. May 2014 B1
8734483 Tekulve et al. May 2014 B2
8735777 Janardhan et al. May 2014 B1
8747432 Janardhan et al. Jun 2014 B1
8747453 Amplatz et al. Jun 2014 B2
8747462 Hill et al. Jun 2014 B2
8747597 Rosqueta et al. Jun 2014 B2
8753371 Janardhan et al. Jun 2014 B1
8758426 Hood et al. Jun 2014 B2
8764772 Tekulve Jul 2014 B2
8764787 Ren Jul 2014 B2
8777974 Amplatz et al. Jul 2014 B2
8777979 Shrivastava et al. Jul 2014 B2
8778008 Amplatz et al. Jul 2014 B2
8783151 Janardhan et al. Jul 2014 B1
8784446 Janardhan et al. Jul 2014 B1
8789452 Janardhan et al. Jul 2014 B1
8790365 Janardhan et al. Jul 2014 B1
8795316 Balgobin et al. Aug 2014 B2
8795319 Ryan et al. Aug 2014 B2
8795330 Janardhan et al. Aug 2014 B1
8803030 Janardhan et al. Aug 2014 B1
8813625 Janardhan et al. Aug 2014 B1
8816247 Janardhan et al. Aug 2014 B1
8821529 Kariniemi et al. Sep 2014 B2
8821849 Schwartz Sep 2014 B2
8828043 Chambers Sep 2014 B2
8828045 Janardhan et al. Sep 2014 B1
8828051 Javois et al. Sep 2014 B2
8845678 Janardhan et al. Sep 2014 B1
8845679 Janardhan et al. Sep 2014 B1
8852227 Janardhan et al. Oct 2014 B1
8859934 Janardhan et al. Oct 2014 B1
8863631 Janardhan et al. Oct 2014 B1
8866049 Janardhan et al. Oct 2014 B1
8869670 Janardhan et al. Oct 2014 B1
8870901 Janardhan et al. Oct 2014 B1
8870910 Janardhan et al. Oct 2014 B1
8872068 Janardhan et al. Oct 2014 B1
8876849 Kratzberg et al. Nov 2014 B2
8882787 Brenzel et al. Nov 2014 B2
8882797 Janardhan et al. Nov 2014 B2
8895891 Janardhan et al. Nov 2014 B2
8900287 Amplatz et al. Dec 2014 B2
8904914 Janardhan et al. Dec 2014 B2
8905961 Braido et al. Dec 2014 B2
8906057 Connor et al. Dec 2014 B2
8910555 Janardhan et al. Dec 2014 B2
8945170 Paul, Jr. Feb 2015 B2
9011476 Sideris Apr 2015 B2
9295571 Newell et al. Mar 2016 B2
9579104 Beckham et al. Feb 2017 B2
9770234 Sideris et al. Sep 2017 B2
10398441 Warner et al. Sep 2019 B2
10405866 Chakraborty et al. Sep 2019 B2
10952740 Dasnurkar et al. Mar 2021 B2
20010000797 Mazzochi May 2001 A1
20010012949 Forber Aug 2001 A1
20020042628 Chin et al. Apr 2002 A1
20020082638 Porter et al. Jun 2002 A1
20020111647 Khairkhahan et al. Aug 2002 A1
20020123759 Amplatz Sep 2002 A1
20020143349 Gifford, III et al. Oct 2002 A1
20020156499 Konya et al. Oct 2002 A1
20020165572 Saadat Nov 2002 A1
20020189727 Peterson Dec 2002 A1
20030023299 Amplatz et al. Jan 2003 A1
20030199919 Palmer et al. Jun 2003 A1
20030167068 Amplatz Sep 2003 A1
20030220666 Mirigian et al. Nov 2003 A1
20040044361 Frazier et al. Mar 2004 A1
20040049210 VanTassel et al. Mar 2004 A1
20040193206 Gerberding Sep 2004 A1
20050065484 Watson, Jr. Mar 2005 A1
20050070952 Devellian Mar 2005 A1
20050228434 Amplatz et al. Oct 2005 A1
20050234543 Glaser et al. Oct 2005 A1
20050288706 Widomski et al. Dec 2005 A1
20060161110 Lenker Jul 2006 A1
20060206139 Tekulve Sep 2006 A1
20060206193 Chobotov et al. Sep 2006 A1
20060241690 Amplatz et al. Oct 2006 A1
20060247680 Amplatz et al. Nov 2006 A1
20070055302 Henry et al. Mar 2007 A1
20070066993 Kreidler Mar 2007 A1
20070112380 Figulla et al. May 2007 A1
20070135826 Zaver et al. Jun 2007 A1
20070167980 Figulla et al. Jul 2007 A1
20070179520 West Aug 2007 A1
20070233186 Meng Oct 2007 A1
20070239192 Litzenberg et al. Oct 2007 A1
20070270891 McGuckin, Jr. Nov 2007 A1
20080033480 Hardert Feb 2008 A1
20080097495 Feller, III et al. Apr 2008 A1
20080103585 Monstadt et al. May 2008 A1
20080119887 Que et al. May 2008 A1
20080249562 Cahill Oct 2008 A1
20080262518 Freudenthal Oct 2008 A1
20080281350 Sepetka et al. Nov 2008 A1
20080306504 Win et al. Dec 2008 A1
20090018562 Amplatz et al. Jan 2009 A1
20090062845 Tekulve Mar 2009 A1
20090082803 Adams et al. Mar 2009 A1
20090187214 Amplatz et al. Jul 2009 A1
20090209855 Drilling et al. Aug 2009 A1
20090216263 Tekulve Aug 2009 A1
20100010517 Stopek et al. Jan 2010 A1
20100030200 Strauss et al. Feb 2010 A1
20100106235 Kariniemi et al. Apr 2010 A1
20100160847 Braido et al. Jun 2010 A1
20100318097 Ferrera et al. Dec 2010 A1
20100324586 Miles et al. Dec 2010 A1
20110040324 McCarthy et al. Feb 2011 A1
20110046719 Frid Feb 2011 A1
20110082491 Sepetka et al. Apr 2011 A1
20110118776 Chen et al. May 2011 A1
20110265943 Rosqueta et al. Nov 2011 A1
20110276080 Nigon Nov 2011 A1
20110295298 Moszner Dec 2011 A1
20110301630 Hendriksen et al. Dec 2011 A1
20120041472 Tan et al. Feb 2012 A1
20120046683 Wilson et al. Feb 2012 A1
20120143008 Wilkins et al. Jun 2012 A1
20120172928 Eidenschink et al. Jul 2012 A1
20120215152 Levine et al. Aug 2012 A1
20120239066 Levine Sep 2012 A1
20120245668 Kariniemi et al. Sep 2012 A1
20120330341 Becking et al. Dec 2012 A1
20120330348 Strauss et al. Dec 2012 A1
20130012979 Amplatz et al. Jan 2013 A1
20130018413 Oral et al. Jan 2013 A1
20130085521 Lim Apr 2013 A1
20130138136 Beckham et al. May 2013 A1
20130190798 Kapadia Jul 2013 A1
20130211443 Cragg et al. Aug 2013 A1
20130245667 Marchand et al. Sep 2013 A1
20130274868 Cox et al. Oct 2013 A1
20140172001 Becking et al. Jun 2014 A1
20140172004 De Canniere Jun 2014 A1
20140222132 Boucher et al. Aug 2014 A1
20160192912 Kassab et al. Jul 2016 A1
20170042549 Kaplan et al. Feb 2017 A1
20180338767 Dasnurkar et al. Nov 2018 A1
20210330333 Gray et al. Oct 2021 A1
Foreign Referenced Citations (18)
Number Date Country
102438533 May 2012 CN
1691879 Aug 2006 EP
1994887 Nov 2008 EP
2003-529410 Oct 2003 JP
2007-519498 Jul 2007 JP
2008536620 Sep 2008 JP
2012523943 Oct 2012 JP
WO2000072909 Dec 2000 WO
WO 2001030266 May 2001 WO
WO2014146001 Sep 2004 WO
WO 2005074814 Aug 2005 WO
WO 2005074814 Aug 2005 WO
WO2006115689 Nov 2006 WO
WO2010123821 Oct 2010 WO
WO2013005195 Jan 2013 WO
WO 2013068466 May 2013 WO
WO2014144980 Sep 2014 WO
WO2014145005 Sep 2014 WO
Related Publications (1)
Number Date Country
20190336132 A1 Nov 2019 US
Provisional Applications (2)
Number Date Country
61924662 Jan 2014 US
61919667 Dec 2013 US
Continuations (1)
Number Date Country
Parent 14575308 Dec 2014 US
Child 16516158 US